To further verify that the effect of EM2 depends on the activation of MST1/2, we jointly treated NSCLC cells with XMU‐MP‐1 (an MST1/2 kinase inhibitor) and EM2. The gene discussed is MST1; the disease is non-small cell lung carcinoma.